Boothbay Fund Management, LLC Blueprint Medicines Corp Transaction History

Boothbay Fund Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $244,673 - $301,110	-2,596 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $30,691 - $41,489	-379 Reduced 12.74%	2,596 $267,000
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $47,764 - $58,277	577 Added 24.06%	2,975 $262,000
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $217,522 - $259,655	2,398 New	2,398 $233,000
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $1.61 Million - $2.25 Million	-24,283 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $1.39 Million - $1.92 Million	24,283 New	24,283 $1.89 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $357,210 - $496,909	-4,900 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $88,542 - $117,751	-1,204 Reduced 19.72%	4,900 $462,000
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $63,163 - $112,320	-1,297 Reduced 17.52%	6,104 $489,000
Q4 2018 Feb 14, 2019	BUY	$45.57 - $74.26 $71,909 - $117,182	1,578 Added 27.1%	7,401 $399,000
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $343,032 - $456,057	5,823 New	5,823 $455,000

340

62M

987K

578K

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.37B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.